TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Venus Concept ( (VERO) ) has shared an update.
On September 19, 2025, Venus Concept Inc. secured a twelfth delayed drawdown of $2,000,000 under its Loan and Security Agreement with Madryn Health Partners, intended for general working capital. Additionally, the board approved transaction completion bonuses for executives Rajiv De Silva and Domenic Della Penna, contingent upon the successful completion of a strategic transaction involving a change of control.
The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
Spark’s Take on VERO Stock
According to Spark, TipRanks’ AI Analyst, VERO is a Underperform.
Venus Concept’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and high leverage. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and no dividend yield. While the earnings call highlighted some strategic improvements, these are insufficient to offset the broader financial challenges.
To see Spark’s full report on VERO stock, click here.
More about Venus Concept
Venus Concept Inc. operates in the medical aesthetics industry, providing advanced technology and services focused on non-invasive and minimally invasive aesthetic solutions. The company targets global markets with its innovative devices designed for skin tightening, body contouring, and other cosmetic procedures.
Average Trading Volume: 374,758
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.26M
For a thorough assessment of VERO stock, go to TipRanks’ Stock Analysis page.